Apart from the TLR-7 agonists discussed here, recent and ongoing clinical trials reporting on immunotherapy for bladder cancer predominantly assess systemic checkpoint inhibitors (for example PD-L1, PD-1 and CTL-A4) targeting advanced and metastatic disease [30, 31]. Here, CTLA4 is linked to urinary bladder cancer.